myNEO Therapeutics Company Overview
myNEO Therapeutics is a distinguished biopharmaceutical company dedicated to pioneering breakthrough immunotherapies to fight cancer. They are leveraging their discovery of the ImmunoEngine platform to tap into promising tumor targets found in the dark genome, named camyotopes, which have the potential to unlock immunotherapy for large patient populations who currently do not respond. They are partners with Janssen and Johnson & Johnson.
myNEO Therapeutics Stock Price
The stock price of myNEO Therapeutics can be calculated by taking the valuation of the company divided by the number of shares outstanding. Because a private company can issue new shares at any time, we do not know the current number of shares outstanding.
Buy myNEO Therapeutics Stock
If you would like to buy shares in myNEO Therapeutics, please provide your information in the form at the top of this page and click the button titled “I want to buy this stock.”
One of our investor relations team members will contact you to discuss myNEO Therapeutics stock availability. Note: inquiries are non-binding and shares may only be purchased by accredited investors that meet all eligibility criteria.
UpMarket has offered many similar companies as Pre-IPO investments, including Airbnb, SpaceX, ByteDance, Plaid, Kraken, Databricks, and others. UpMarket also often has funds available that invest in a portfolio of companies potentially including, myNEO Therapeutics as well.
myNEO Therapeutics Management
Name | Position |
---|---|
Cedric Bogaert | CEO |
Bert Coessens | COO |
Bruno Fant | CTO |